{
    "clinical_study": {
        "@rank": "77492", 
        "brief_summary": {
            "textblock": "To evaluate the pharmacokinetics of Retrovir (AZT) administered orally as 1 of 3 doses in\n      the treatment of patients with severe clinical and laboratory manifestations of HIV\n      infection. To compare the safety and tolerance of AZT administered 2, 3, and 6 x daily to\n      these patients."
        }, 
        "brief_title": "A Dose-Frequency Trial of Oral Retrovir in Patients With AIDS or Severe ARC", 
        "condition": "HIV Infections", 
        "condition_browse": {
            "mesh_term": [
                "HIV Infections", 
                "Acquired Immunodeficiency Syndrome"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria\n\n        Concurrent Treatment:\n\n        Allowed:\n\n          -  Electron beam therapy to an area of less than 100 cm2.\n\n        Patients with the following are excluded:\n\n          -  Any immediately life-threatening infection or medical condition present at the time\n             of study entry.\n\n          -  Any active opportunistic or other infection requiring chronic therapy present at the\n             time of study entry.\n\n          -  Patients with Pneumocystis carinii pneumonia (PCP) may be randomized to study\n             medication following a minimum 7-day course of therapy resulting in stabilization of\n             their disease. Patients with stabilized disease must have fever < 39 degrees C for at\n             least 48 hours; oxygen (on room air)\n\n             = or > 60 mm, and arterial / alveolar gradient = or < 30 mm.\n\n          -  Kaposi's sarcoma, lymphoma, or other tumor likely to require cytotoxic chemotherapy.\n\n        Seropositive for HIV antibody documented by any federally licensed ELISA.\n\n        Patients must have ability to give informed consent and advanced HIV disease defined as:\n\n        - History of Pneumocystis carinii pneumonia (PCP) with histologic verification within 4\n        months of study entry.\n\n        OR History of other opportunistic infection included in the CDC surveillance definition of\n        AIDS (stage IV-C-1), diagnosed within 4 months of entry, but not requiring chronic\n        suppressive therapy, and a CD4+ cell count < 200 cells/mm3.\n\n        OR AIDS related complex (ARC) only those patients with a CD4+ count < 200 cells/mm3 and\n        documentation of at least two signs or symptoms from the list below. One sign or symptom\n        must be weight loss or candidiasis as described.\n\n          -  Unexplained weight loss > 10 percent or = or > 15 lbs within the previous 4 months;\n             with low weight at entry.\n\n          -  History of mucocutaneous oral candidiasis (by culture or potassium hydroxide KOH\n             smear).\n\n          -  Fever > 38 degrees C, without documented infectious cause present, persisting > 1\n             month.\n\n          -  Oral hairy leukoplakia.\n\n          -  Unexplained night sweats, persisting > 1 month.\n\n          -  Herpes zoster infection within 3 months of entry.\n\n          -  Chronic diarrhea of unknown infectious etiology persisting > 1 month after 3 samples\n             have been done eliminating ova, parasites, Cryptosporidia, Mycobacterium avium\n             intracellulare, cytomegalovirus (CMV), and other pathogens associated with diarrheal\n             disease in AIDS patients.\n\n        Negative Venereal Disease Research Laboratory (VDRL) or Rapid Plasma Reagent (RPR) or, if\n        positive and verified by Fluorescent Treponemal Antibody Absorption (FTAABS), documented\n        history of treatment for syphilis. If FTAABS is positive, but treatment history is not\n        available, the patient may be entered 3 or more days following the initiation of\n        appropriate chemotherapy.\n\n        Exclusion Criteria\n\n        Co-existing Condition:\n\n        Patients with the following are excluded:\n\n          -  Chronic herpes virus infection.\n\n          -  Fever > 39 degrees C at study entry.\n\n          -  Known hypersensitivity to lactate and/or gelatin.\n\n          -  Kaposi's sarcoma, lymphoma, or other tumor likely to require cytotoxic chemotherapy.\n\n          -  Impaired renal function.\n\n          -  AIDS dementia complex.\n\n        Concurrent Medication:\n\n        Excluded:\n\n          -  Drugs which cause significant bone marrow suppression.\n\n          -  Rifampin or rifampin derivatives.\n\n          -  Drugs which cause significant nephrotoxicity or hepatotoxicity.\n\n          -  Antiretroviral agents, including ribavirin, dideoxycytidine, dideoxyadenosine,\n             didanosine, foscarnet, dextran sulfate, and AL-721.\n\n          -  Acyclovir therapy of more than 21 days duration.\n\n        Concurrent Treatment:\n\n        Excluded:\n\n          -  Radiation therapy (with the exception of electron beam therapy to an area of less\n             than 100 cm2).\n\n          -  Experimental therapy.\n\n          -  Cytolytic chemotherapy.\n\n        Prior Medication:\n\n        Excluded:\n\n          -  Acyclovir therapy of more than 21 days duration.\n\n          -  Zidovudine (AZT).\n\n          -  Excluded within 2 weeks of study entry:\n\n          -  Drugs which cause significant bone marrow suppression.\n\n          -  Rifampin or rifampin derivatives.\n\n          -  Drugs which cause significant nephrotoxicity or hepatotoxicity.\n\n          -  Immunomodulating agents, including pharmacologic doses of steroids for > 10 days.\n\n          -  Excluded within 4 weeks of study entry:\n\n          -  Interferon.\n\n          -  Isoprinosine.\n\n          -  IL-2.\n\n          -  Excluded within 8 weeks of study entry:\n\n          -  Antiretroviral agents, including ribavirin, dideoxycytidine, dideoxyadenosine,\n             didanosine, foscarnet, dextran sulfate, and AL-721.\n\n        Prior Treatment:\n\n        Excluded:\n\n          -  Radiation therapy (with the exception of electron beam therapy to an area of less\n             than 100 cm2).\n\n          -  Experimental therapy.\n\n          -  Cytolytic chemotherapy.\n\n        Active drug or alcohol abuse."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "13 Years"
        }, 
        "firstreceived_date": "November 2, 1999", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT00002046", 
            "org_study_id": "014G", 
            "secondary_id": "18"
        }, 
        "intervention": {
            "intervention_name": "Zidovudine", 
            "intervention_type": "Drug"
        }, 
        "intervention_browse": {
            "mesh_term": "Zidovudine"
        }, 
        "keyword": [
            "Acquired Immunodeficiency Syndrome", 
            "AIDS-Related Complex", 
            "Zidovudine"
        ], 
        "lastchanged_date": "June 23, 2005", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Tucson", 
                        "country": "United States", 
                        "state": "Arizona", 
                        "zip": "85724"
                    }, 
                    "name": "Univ of Arizona / Health Science Ctr"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Chicago", 
                        "country": "United States", 
                        "state": "Illinois", 
                        "zip": "60611"
                    }, 
                    "name": "Northwestern Univ Med School"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Chicago", 
                        "country": "United States", 
                        "state": "Illinois", 
                        "zip": "60612"
                    }, 
                    "name": "Rush Presbyterian - Saint Luke's Med Ctr"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Chicago", 
                        "country": "United States", 
                        "state": "Illinois", 
                        "zip": "60612"
                    }, 
                    "name": "Cook County Hosp"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Baltimore", 
                        "country": "United States", 
                        "state": "Maryland", 
                        "zip": "21205"
                    }, 
                    "name": "Johns Hopkins Hosp"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Kansas City", 
                        "country": "United States", 
                        "state": "Missouri", 
                        "zip": "64108"
                    }, 
                    "name": "Univ of Missouri at Kansas City School of Medicine"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Albuquerque", 
                        "country": "United States", 
                        "state": "New Mexico", 
                        "zip": "87131"
                    }, 
                    "name": "Univ of New Mexico Hlth Sciences Ctr / Dept of Med"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Manhasset", 
                        "country": "United States", 
                        "state": "New York", 
                        "zip": "11030"
                    }, 
                    "name": "Northshore Hosp / Cornell Univ"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Philadelphia", 
                        "country": "United States", 
                        "state": "Pennsylvania", 
                        "zip": "19104"
                    }, 
                    "name": "Univ of Pennsylvania / HIV Clinic"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Galveston", 
                        "country": "United States", 
                        "state": "Texas", 
                        "zip": "77550"
                    }, 
                    "name": "Univ TX Galveston Med Branch"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Houston", 
                        "country": "United States", 
                        "state": "Texas", 
                        "zip": "77030"
                    }, 
                    "name": "Baylor College of Medicine"
                }
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "official_title": "A Dose-Frequency Trial of Oral Retrovir in Patients With AIDS or Severe ARC", 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration"
        }, 
        "phase": "N/A", 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT00002046"
        }, 
        "source": "NIH AIDS Clinical Trials Information Service", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Glaxo Wellcome", 
                "agency_class": "Industry"
            }
        }, 
        "study_design": "Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 1990"
    }, 
    "geocoordinates": {
        "Baylor College of Medicine": "29.76 -95.369", 
        "Cook County Hosp": "41.878 -87.63", 
        "Johns Hopkins Hosp": "39.29 -76.612", 
        "Northshore Hosp / Cornell Univ": "40.798 -73.7", 
        "Northwestern Univ Med School": "41.878 -87.63", 
        "Rush Presbyterian - Saint Luke's Med Ctr": "41.878 -87.63", 
        "Univ TX Galveston Med Branch": "29.301 -94.798", 
        "Univ of Arizona / Health Science Ctr": "32.222 -110.926", 
        "Univ of Missouri at Kansas City School of Medicine": "39.1 -94.579", 
        "Univ of New Mexico Hlth Sciences Ctr / Dept of Med": "35.084 -106.651", 
        "Univ of Pennsylvania / HIV Clinic": "39.952 -75.164"
    }
}